The overarching goal of the IMI DIRECT (Innovative Medicines Initiative Diabetes Research on Patient Stratification) Consortium is the identification of biomarkers that aid therapeutic targeting in prediabetes (Study 1) or early onset type 2 diabetes (Study 2).
There are two multicentre prospective cohort studies within the glycaemic deterioration work package of IMI DIRECT (WP2). These two cohorts are designed to address the area of glycaemic deterioration by amassing data and biomaterials that will be used to discover novel biomarkers for glycaemic deterioration in people at high risk of developing type 2 diabetes (Study 1) and in those who have recently been diagnosed with the disease (Study 2).
Study Type
OBSERVATIONAL
Enrollment
3,049
Glycemic deterioration
Change in glucose (or HbA1c) over time and/or progression to anti diabetic medications/insulin
Time frame: Up to 10 years follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.